Breaking the silence: challenges and opportunities in pediatric drug development.

Abstract

Pediatric drug development faces significant challenges, including underfunding, ethical concerns, and complex regulatory frameworks. Despite significant advances in adult drug development, children remain underserved due to their unique physiological needs and difficulties conducting clinical trials. Current pediatric therapeutic options are limited, off-label, and lack evidence from well-controlled trials. Incorporating global regulatory frameworks can provide valuable insights when addressing these challenges. The disparity in investment is evident as several pharmaceutical companies have recently closed their pediatric drug centers with plans to focus on more profitable adult markets, leaving pediatric research underprioritized. This article discusses the root causes of this imbalance and potential solutions including: 1) the use of emerging technologies - artificial intelligence, modeling, and simulation; 2) leveraging innovative trial designs, 3) the use of real-world data, 4) the need for public-private partnerships to drive progress in pediatric drug development; and 5) advocacy groups to shape policies and investments. By focusing on enhancing regulatory incentives, encouraging long-term industry commitment, and engaging patient advocacy groups, a more sustainable pipeline can be established. This call to action underscores the moral imperative of prioritizing pediatric health and fostering innovation to improve outcomes for vulnerable pediatric populations and shape a healthier future for all children. IMPACT: Pediatric drug development faces significant challenges, including underfunding, ethical concerns, and complex regulatory frameworks. The most important causes include the absence of robust advocacy, regulatory hurdles, and economic disincentives. Potential solutions involve leveraging innovative trial designs, the use of real-world data, and public-private partnerships.